Looks like efficacy seen in renal cell carcinoma , bone mets from an unknown primary cancer and non small cell lung cancer . NSCLC is one of the most common cancers . All patients had exhausted all approved treatments . Renal cell patient now in good health and the NSCLC patient is still to receive another cycle in late Feb .
- Forums
- ASX - By Stock
- cancer trial update
SBP
solbec pharmaceuticals limited
Looks like efficacy seen in renal cell carcinoma , bone mets...
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online